UNSPSC 51283610: Rifamycin s

This classification denotes an antitubercular agent with the molecular formula C37H45NO12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PI53N820JV, chemically known as 1,4-dideoxy-1,4-dihydro-1,4-dioxorifamycin, but more generally known as rifamycin s, which bears US NIH Compound Identifier 5475445. European Medicines Agency schedules rifamycin s or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10310MIG. Most nations, for tariff purposes, schedule rifamycin s under HS 29419000.

SMILES: CC1C(C2C3C4C1O[C@@](C4=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]([C@H](/C=C/C=C(\C(=O)NC(=CC3=O)C2=O)/C)C)O)C)O)C)OC(=O)C)C)OC)C)O.

UNSPSC 51283610 Rifamycin S is a Commodity code that nominally designates a specific antibiotic pharmaceutical, but recent state and local procurement activity tagged to this code does not reflect purchases of rifamycin S itself. Instead, the code appears in solicitations for broader pharmaceutical and medical supply procurement — including naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products, medical and first aid supplies for emergency response, and direct-to-manufacturer pharmacy programs. State and local issuing bodies using this code span county health departments, state health and human services commissions, municipal fire and rescue divisions, and cooperative purchasing alliances serving multiple jurisdictions. The actual procurement activity under this code designation reflects a data-classification mismatch rather than the narrow pharmaceutical ingredient the code name implies; vendors pursuing opportunities tagged to this code should expect requests for broader medical supply categories, emergency response consumables, and pharmacy benefit program participation rather than rifamycin S specifically.

Geographic activity includes Florida, Texas, Minnesota, and Oregon across the recent opportunities. Seminole County, Florida posted an IFB (IFB60459723LAS, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for community health initiatives with quarterly deliveries to Sanford. The City of Tampa issued an IFB (26P00145, due March 13, 2026) for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, estimated at $700,000, designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across state and local government facilities in Minnesota and Oregon, with awards effective July 1, 2026. The Texas Health and Human Services Commission posted a Request for Information (HHS0017013, due April 3, 2026) to gather vendor capabilities regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, serving as preliminary market intelligence before formal procurement.